VERONA, Pa. — Residents along Penn Street in Verona, Allegheny County, have been hearing the barks of two dogs left alone inside a home, according to Verona Police Chief Tom Dessell. The dogs ...

Wonder Land Enrichment Center in Verona, Virginia, will close after the Virginia Department of Education declined to renew its license. The DOE cited violations including incomplete background checks, ...

The Augusta County Sheriff's Office announced on June 3 that 25-year-old Blake Clark, of Verona, had been charged with murder following the death of his son. Clark was initially charged with child ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from ...

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential and bullish long-term outlook.

Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company. The one-month return of Verona Pharma plc (NASDAQ:VRNA) was 25.66%, and its shares gained 501.15% of their value over the last 52 weeks.

Here are some of the latest news items happening this morning, Friday, June 20: Dogs retrieved from Verona house after being left alone Two dogs were retrieved Thursday from a Verona home on Penn ...

Brighton & Hove Albion have confirmed the signing of Italian central defender Diego Coppola from Serie A side Hellas Verona. The 21-year-old established himself as a regular for Verona last season ...

Michael Perinelli is a financial advisor in Staten Island, NY. He has been in practice for 14 years, the last 8 years at MML Investors Services LLC.

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year ...